Editorial evidence check: September 17, 2026. Not a new medical review.
Product illustrations. The studies below tested manufacturer medicines, not these compounded preparations.
Four studies. Four different questions.
The original three trials randomized 5,303 participants in total (1,961 + 2,539 + 803). That is a count across separate studies, not a pooled analysis or a trial of REMEVi care. SURMOUNT-5 adds a direct comparison.
STEP 1 · NEJM · 2021
Semaglutide versus placebo
Participants
1,961 adults without diabetes; BMI ≥30, or ≥27 with a weight-related condition.
Treatment
Semaglutide 2.4 mg weekly or placebo, with lifestyle support.
Duration
68 weeks
Finding
14.9% average weight loss versus 2.4% with placebo.
Read with this limit: Manufacturer medicine; not a compounded-product trial. Funded by Novo Nordisk.
Trial averages are not individual forecasts. Do not compare separate trials as though participants and methods were identical. These findings do not establish effectiveness, safety or equivalence for compounded preparations.
A mechanism is not an outcome.
GLP-1 receptor activity helps explain appetite regulation and glucose-dependent insulin release. Tirzepatide also activates GIP receptors. Neither mechanism guarantees a percentage reduction in cravings, calorie intake, HbA1c or preserved muscle.
Benefits and risks depend on the product, dose, population and outcome studied. Review the complete warnings with your clinician.
GLP-1 (7–37) · α-HELIX 31 RESIDUES · 3.6 / TURN DRAG TO ROTATE · CLICK A RESIDUE
Simplified 31-position teaching model. The tirzepatide view is schematic: it does not represent its actual 39-amino-acid sequence. Specifications describe the molecules in approved medicines; they do not verify a compounded preparation. Wegovy · Zepbound
FIG. 00 · SEMAGLUTIDE C₁₈₇H₂₉₁N₄₅O₅₉
HYDROPHOBIC
POLAR
POSITIVE
NEGATIVE
MODIFIED
· SPEC SHEET ·NEJM 2021 · STEP-1
Semaglutide
Long-acting analog · 31 aa
Molecular formulaC₁₈₇H₂₉₁N₄₅O₅₉
Molecular weight4,113 Da
Half-life168 hrs (7 days)
Dose cadenceOnce-weekly
Receptor(s)GLP-1R
· RESIDUE · ANNOTATION ·
Lys²⁶ · semaglutide attachment
A C18 fatty diacid and linker promote albumin binding, contributing to prolonged action. See section 11 of the Wegovy prescribing information.
· WHERE IT ACTS · DÓNDE ACTÚA ·MECHANISMS, NOT PROMISED RESULTS
Appetite
Brain
GLP-1 pathways
Appetite and calorie intake can change; response varies.
Digestion
Stomach
Gastric emptying
Emptying can be delayed. Digestive adverse effects also matter.
Glucose
Pancreas
Glucose-dependent action
Insulin and glucagon regulation; low glucose risk rises with certain diabetes drugs.
Body composition
Muscle
No preservation guarantee
Weight loss can include lean tissue. Discuss nutrition and strength with your clinician.
Answers for your next step.
Bring the evidence to your visit.
Ask how the exact medicine, expected benefits, risks and full cost fit your situation.
